Omata Fumio, Ohde Sachiko, Deshpande Gautam A, Kobayashi Daiki, Masuda Katsunori, Fukui Tsuguya
Department of Internal Medicine, St. Luke's International Hospital , Chuo-Ku , Japan.
Scand J Gastroenterol. 2014 Feb;49(2):222-37. doi: 10.3109/00365521.2013.863964. Epub 2013 Dec 16.
The effectiveness of narrow band imaging (NBI), chromoendoscopy (CE), and cap-assisted colonoscopy (CAC) on adenoma detection rate (ADR) has been investigated in previous meta-analyses; however, there have been no meta-analyses of autofluorescence imaging (AFI) or flexible spectral imaging color enhancement (FICE) or i-scan. The aim of this study was to determine whether AFI and FICE/i-scan was more effective than standard/high-definition white light endoscopy to improve ADR and to update previous meta-analyses of NBI, CE, and CAC.
A systematic review and meta-analysis was conducted. Four investigators selected appropriate randomized controlled trials (RCT) using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline. All RCTs in which colonoscopy were performed with AFI, FICE, i-scan, NBI, CE, and CAC were included. The risk ratios (RRs) calculated from adenoma/neoplasia detection rate were used as the main outcome measurement.
A total of 42 studies were included in the analysis. Pooled estimates of RR (95%confidence interval [CI]) using AFI, FICE/i-scan, NBI, CE, and CAC were 1.04 (95% CI: 0.87-1.24) (I² = 0%) (fixed effects model [FEM]); 1.09 (95% CI: 0.97-1.23) (I² = 5%) (FEM); 1.03 (95% CI: 0.96-1.11) (I² = 0%) (FEM); 1.36 (95% CI: 1.23-1.51) (I² = 16%) (FEM); and 1.03 (95% CI: 0.93-1.14) (I² = 48%) (random effects model [REM]), respectively. The pooled estimate of RR (95%CI) using indigo carmine in non-ulcerative colitis (UC) patients and methylene blue in UC patients was 1.33 (95% CI: 1.20-1.48) (I² = 14%) (FEM) and 2.39 (95% CI: 1.18-4.84) (I² = 0%) (FEM), respectively.
In contrast to AFI, FICE/i-scan, NBI, and CAC, only CE improves ADR. CE with methylene blue, though not NBI, is effective for surveillance of neoplasia in chronic UC patients.
既往的荟萃分析研究了窄带成像(NBI)、色素内镜检查(CE)和胶囊辅助结肠镜检查(CAC)对腺瘤检出率(ADR)的有效性;然而,尚未有对自体荧光成像(AFI)、灵活光谱成像色彩增强(FICE)或i-scan的荟萃分析。本研究的目的是确定AFI和FICE/i-scan是否比标准/高清白光内镜检查在提高ADR方面更有效,并更新之前关于NBI、CE和CAC的荟萃分析。
进行了一项系统评价和荟萃分析。四名研究人员使用系统评价和荟萃分析的首选报告项目(PRISMA)指南选择了合适的随机对照试验(RCT)。纳入了所有使用AFI、FICE、i-scan、NBI、CE和CAC进行结肠镜检查的RCT。从腺瘤/肿瘤检出率计算得出的风险比(RRs)用作主要结局指标。
分析共纳入42项研究。使用AFI、FICE/i-scan、NBI、CE和CAC的RR(95%置信区间[CI])的合并估计值分别为1.04(95%CI:0.87-1.24)(I² = 0%)(固定效应模型[FEM]);1.09(95%CI:0.97-1.23)(I² = 5%)(FEM);1.03(95%CI:0.96-1.11)(I² = 0%)(FEM);1.36(95%CI:1.23-1.51)(I² = 16%)(FEM);以及1.03(95%CI:0.93-1.14)(I² = 48%)(随机效应模型[REM])。在非溃疡性结肠炎(UC)患者中使用靛胭脂和在UC患者中使用亚甲蓝的RR(95%CI)的合并估计值分别为1.33(95%CI:1.20-1.48)(I² = 14%)(FEM)和2.39(95%CI:1.18-4.84)(I² = 0%)(FEM)。
与AFI、FICE/i-scan、NBI和CAC不同,只有CE能提高ADR。亚甲蓝染色的CE,而非NBI,对慢性UC患者的肿瘤监测有效。